Skip to NavigationSkip to content

Axon seeks global partner after positive Phase 2 data for Alzheimer’s vaccine

Published on 10/09/19 at 10:32am

Axon Neuroscience has announced data from its Phase 2 trial ADAMANT for the first-in-class vaccine AADvac1 to slow the progression of Alzheimer’s disease.

Although the primary objective of the trial was safety, the trial data indicated a statistically significant improvement in a biomarker associated with the initial onset of Alzheimer’s – that being neuronal loss measured by Neurofilament Light Chain (NfL) in the blood. The data in this biomarker ultimately means that AADvac1 slows the progression of neurodegenerative processes to levels typically seen in healthy individuals.

The trial, involving 196 patients in eight European countries over 24 months, also managed to produce a highly effective immune response with 98.2% of patients generating antibodies against pathological tau.

Michal Fresser, CEO at Axon Neuroscience, said: “Today’s results mark an important milestone for Axon and for the entire population of the world that suffers from this devastating disease.

“These results strongly reveal a disease-modifying effect on the disease [and] underpin our confidence to taken the next steps in bringing a life-changing treatment to patients as soon as possible.”

The news comes after multiples failures in the Alzheimer’s department from Eli Lilly, Biogen, and MSD as researchers are being forced to rethink the amyloid hypothesis and focus on other areas such as targeting nuerofibrally tangles called ‘tau’.

Nik Kiran

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches